MarketVIEW Pipeline Report  ·  November 2026 Edition

Strategic Vaccine &
mRNA Pipeline Review

The most comprehensive independent analysis of the global industry vaccine and mRNA clinical trial landscape - 2,178 Phase I-IV trials, 104 pathogens, 270 companies. Now with 70 verified active programmes from 8 large developers, refreshed October 2026, and a dedicated mRNA landscape focus section.

mRNA Deep-dive Phase I-IV Coverage November 2026 Update 2,178 Trials 70 Verified Programmes DNA Landscape
Product catalogue
VAMV084B
Published November 2026

Previous edition
VAMV084A (June 2026)
Format
MS Excel workbook
Trials covered
2,178
Verified active programmes
70 (8 developers)
Pipeline refresh
October 2026
Companies
~270
Pathogens
104
Market segments
16
Data start date
Jan 2014
2,178
Clinical trials
Phase I-IV
~270
Industry
companies
104
Pathogens &
conditions
237
mRNA vaccine
trials identified
16
Market
segments
Interactive preview

Explore the verified pipeline yourself

Compare the large developers at a glance, then filter every verified active programme by phase, pathogen and segment, or play the tracker to see how the pipeline has grown since 2021. Programme status is as verified in October 2026.

70verified active programmes
8large developers profiled
31in novel segments (no licensed vaccine market)
17in Phase 3, the next likely approvals
8new since May 2026
Open the interactive pipeline →
Scope of analysis

Twelve layers of analysis in one workbook

Each trial has been curated and annotated with new fields that go far beyond the raw ClinicalTrials.gov export - enabling market-ready competitive intelligence outputs.

🧬
mRNA & nucleic acid landscape

Dedicated mRNA and DNA scan across all trials. Platform identification by company tier, market segment and pathogen. saRNA/replicon programmes flagged separately.

🦠
Pathogen & condition ranking

104 pathogens ranked by trial volume (completed + ongoing). New vs. existing segment designation. Coverage spans infectious disease, oncology and chronic conditions.

📊
Market segment analysis

16 segments including COVID-19, Novel, Oncology, Influenza, RSV, Pediatric, Travel/endemic, Pneumococcal. Volume and nucleic acid penetration by segment.

🏢
Company size stratification

Small (<$100m), Medium ($100-500m) and Large (>$500m vaccine revenues/yr) developer tiers. 37 large, 16 medium, 200+ small companies catalogued.

⚗️
Platform & production system

19 vaccine platform types classified per programme - from mRNA to polysaccharide conjugates. Adjuvantation status and adjuvant type captured for verified programmes.

✅
Verified active programme list

Curated list of 70 confirmed active programmes from 8 large developers (Phase 1 to Phase 3, refreshed October 2026) - separate from raw trial registry data. Expert-audited with source references and a change log since May 2026.

mRNA Focus Section

The mRNA vaccine pipeline - identified, classified, ranked

This edition includes the most comprehensive independent tracking of mRNA vaccine programmes across all disease areas - not just COVID-19. The analysis identifies emerging seasonal influenza combinations, RSV pipelines and non-infectious disease applications in oncology. Of the 70 verified active programmes, 38 are nucleic-acid based (mRNA, mRNA neoantigen or saRNA), led by Moderna (15), BioNTech (8), Pfizer (5) and Sanofi (5).

COVID-19
88
Influenza
38
RSV
21
Novel (non-ID)
26
Oncology
19
Travel/endemic
10

mRNA trials identified by title scan (Phase I-IV, industry only, data cut 22 October 2026)

Key programmes tracked (October 2026 status)

  • ModernamRNA-1010 Seasonal influenza Phase 3
  • ModernamRNA-1403 Norovirus Phase 3
  • ModernamRNA-1018 Pandemic influenza Phase 3
  • ModernamCOMBRIAX Flu/COVID-19 combination Licensed
  • BioNTechBNT161 Influenza Phase 3
  • MSDV940 mRNA neoantigen, melanoma and NSCLC Phase 3
  • PfizerPF-07252220 Influenza mRNA, plus PF-07845104 saRNA
  • GSKGSK4382276 Influenza mRNA
  • SanofiSP0289 Pandemic (H5) influenza mRNA
  • BioNTechBNT166 Mpox mRNA

Plus the remaining nucleic-acid programmes, discontinued candidates and oncology-focused mRNA neoantigen programmes - full universe covered in the workbook. Explore them interactively.

Pathogen & condition coverage

104 pathogens ranked - from COVID-19 to rare biodefense agents

Every pathogen and condition is ranked by trial volume and categorised by new vs. existing vaccine. A sample of the coverage is shown below - the full ranked list is in the workbook.

COVID-19 Influenza RSV Pneumococcal Meningococcal HPV HIV Herpes Zoster Malaria Poliomyelitis Dengue Fever Rabies Rotavirus Cytomegalovirus Tuberculosis Chikungunya Hepatitis B Lung cancer Melanoma Multiple cancers Brain cancer Cervical cancer Pancreatic cancer Norovirus Ebola Typhoid Fever Cholera Shigellosis Zika Virus EBV Lyme Borreliosis Monkeypox Nipah Virus Crimean-Congo HF Japanese Encephalitis C. difficile Staphylococcus aureus + 67 more →

Tags sized by trial volume. Gold = oncology. Full ranked list with trial counts, new/existing designation and market segment in the workbook.

Sample data

A glimpse of the pipeline - by pathogen and market segment

The table below shows a partial view of the pathogen-level breakdown. The full workbook contains 9 linked summary sheets, ranked tables, nucleic acid analysis and company-level breakdowns across all 16 segments.

Rank Pathogen / Condition Trials (Ph I-IV) New vaccine? Market segment mRNA trials
1COVID-19386NewCOVID-1988
2Influenza259ExistingInfluenza38
3Respiratory Syncytial Virus153NewRSV21
4Pneumococcal135ExistingPneumococcal0
5Meningococcal Infections91ExistingMeningococcal0
6████████████████████████████████
7████████████████████████████
8████████████████████Existing█████████
9███████████████████████████
10████████████████████████
🔒
Full table in the licensed workbook
104 pathogens · ranked · linked to all 9 summary sheets
Request access →
Deliverables

What you receive

The licensed workbook is a self-contained intelligence tool - not a flat data dump. All summary sheets are formula-driven and cross-linked.

  • MS Excel workbook (.xlsb) - fully formula-driven, 40+ linked worksheets covering all analysis dimensions
  • Industry trials master dataset - 2,178 trials with 27 annotated fields per trial including company type, platform, market segment and duration
  • 9 summary analysis sheets - pathogen ranking, market segment breakdown, nucleic acid landscape, company-level mRNA/DNA, platform type distribution and more
  • mRNA landscape section - company-level mRNA programme counts, platform classification, saRNA identification and non-ID/oncology focus
  • Verified active programme list - expert-audited list of 70 confirmed pipeline programmes from 8 large developers with phase, segment, platform type, adjuvantation status and source references, plus the October 2026 change log
  • Company analysis - Large (37 companies), Medium (16), Small (200+) developer tiers with COUNTIF-ready company lists
  • Interactive pipeline explorer - preview it online before you license
  • Access to an executive presentation - PowerPoint deck summarising key outputs, charts and strategic commentary (available as an add-on)
Target audience

Built for strategic decision-makers in vaccines

This analysis is designed for organisations where competitive intelligence directly informs investment, licensing or development strategy.

💊

Pharma & biotech BD

Licensing, partnering and portfolio gap analysis against a full industry landscape.

📈

Strategy & corporate development

Investment thesis validation, competitive benchmarking, pipeline prioritisation.

🔬

R&D leadership

Platform positioning, pathogen prioritisation and white-space identification.

🏦

Investors & advisors

Evidence-based pipeline assessment for due diligence and sector positioning.

🏛️

Government & procurement

Understanding the commercial pipeline landscape for procurement planning.

📋

Market access & HEOR

Competitive context for payer submissions and value dossiers.

About this analysis · VAMV084B

Analysis of the vaccine R&D pipeline is a critical component of any organisation's competitive intelligence effort - informing strategic portfolio management, business development, R&D prioritisation and corporate investment. The key challenge is that the pipeline is highly dynamic, and a historical view requires skilled judgement during curation, especially when assigning new analytical fields.

This November 2026 edition has been independently curated and annotated by VacZine Analytics, building on continuous pipeline coverage since 2007. The mRNA landscape focus section represents a significant new addition, reflecting the rapid maturation of mRNA technology beyond COVID-19 into influenza, RSV and oncology applications. It remains the only independently curated, industry-wide trial dataset of its kind available for licence.

MarketVIEW · VAMV084B · Pipeline Intelligence

License the Strategic Vaccine & mRNA Pipeline Review

Contact VacZine Analytics for pricing, sample worksheets and licensing terms. Single-licence and multi-user options available. Briefing call included on request.